PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33374546-0 2020 Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model. Diphosphonates 0-15 TNF superfamily member 11 Homo sapiens 83-88 34347277-9 2021 The BP-induced abnormal shift in RANKL/OPG expression ratio in rBM-derived cells was normalized by hUC-MSCs. Diphosphonates 4-6 TNF superfamily member 11 Homo sapiens 33-38 35482061-14 2022 CONCLUSIONS: The BP-stimulated increase in the level of OPG and the decrease in the level of RANKL, as well as the impact on the level of the analyzed interleukins in the bone microenvironment, may be an important element of the mechanisms limiting bone resorption. Diphosphonates 17-19 TNF superfamily member 11 Homo sapiens 93-98 33183068-5 2021 To the contrary, long-term use of anti-osteoporotic drugs such as bisphosphonates and Denosumab, an RANKL inhibitor, have resulted in adverse events. Diphosphonates 66-81 TNF superfamily member 11 Homo sapiens 100-105 12732166-4 2003 In this review, we provide an overview of the RANK/RANKL/osteoprotegerin system; we describe its interaction with other cellular mechanisms, through which malignant plasma cells drive osteolysis, and explain how bisphosphonates can be used to block this action. Diphosphonates 212-227 TNF superfamily member 11 Homo sapiens 51-56 25055746-14 2015 CONCLUSIONS: This study shows for the first time that mechanical loading alters the effects of bisphosphonates on viability, apoptosis rate, and OPG/RANKL system of HPdLF dependent on the applied strength. Diphosphonates 95-110 TNF superfamily member 11 Homo sapiens 149-154 34279472-7 2021 Significant suppression of the RANKL/OPG ratio and Kcnn4 expression among the retrieved bones of IV BP group patients was also noted. Diphosphonates 100-102 TNF superfamily member 11 Homo sapiens 31-36 33374546-5 2020 Our results showed that BPs were able to reduce CSE-induced osteoporotic alterations in the co-culture of osteoblasts and osteoclasts such as decreased matrix remodeling, enhanced osteoclast activation, and an up-regulated receptor activator of nuclear factor (NF)-kB-ligand (RANKL)/osteoprotegerin (OPG) ratio. Diphosphonates 24-27 TNF superfamily member 11 Homo sapiens 276-281 33374546-6 2020 In summary, BPs may be an effective alternative therapy for reversing osteoporotic alterations in smokers, and the potential mechanism is through modulation of the RANKL/OPG ratio. Diphosphonates 12-15 TNF superfamily member 11 Homo sapiens 164-169 27095621-0 2015 Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis. Diphosphonates 10-25 TNF superfamily member 11 Homo sapiens 43-48 30231385-5 2018 We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD. Diphosphonates 91-106 TNF superfamily member 11 Homo sapiens 182-233 31606424-8 2020 Bisphosphonate (P < .001) and mixed necrosis (P = .002) demonstrated more RANKL- and TRAP-positive osteoclasts. Diphosphonates 0-14 TNF superfamily member 11 Homo sapiens 77-82 30949254-2 2019 Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor. Diphosphonates 56-59 TNF superfamily member 11 Homo sapiens 86-145 30949254-2 2019 Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor. Diphosphonates 56-59 TNF superfamily member 11 Homo sapiens 147-152 30949254-2 2019 Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor. Diphosphonates 243-246 TNF superfamily member 11 Homo sapiens 86-145 30949254-2 2019 Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor. Diphosphonates 243-246 TNF superfamily member 11 Homo sapiens 147-152 28367895-0 2017 Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. Diphosphonates 10-24 TNF superfamily member 11 Homo sapiens 143-148 28228794-1 2016 BACKGROUND: We report on the clinical and biochemical outcomes in a 20-year-old male suffering from active craniofacial monostotic fibrous dysplasia (MFD) of the left mandible treated with the RANK-L inhibitor, denosumab, following unsatisfactory responses to prior long-term bisphosphonates therapy. Diphosphonates 276-291 TNF superfamily member 11 Homo sapiens 193-199 26856585-14 2016 CONCLUSIONS: Our study demonstrated the key role of DKK1, RANKL, and TNF-alpha in regulating bone cell activity of subjects with OI untreated and treated with bisphosphonates. Diphosphonates 159-174 TNF superfamily member 11 Homo sapiens 58-63 27095621-7 2015 The aim of this study was to evaluate the levels of RANKL, OPG and their relationship in gingival crevicular fluid (GCF) in patients with periodontal disease and postmenopausal osteoporosis/ osteopenia in relation to consumption of bisphosphonates. Diphosphonates 232-247 TNF superfamily member 11 Homo sapiens 52-57 26614482-7 2015 We demonstrated that microinjury to osteocyte networks being treated with bisphosphonates modulates receptor activator of nuclear factor kappa-B ligand and osteoprotegerin activity, and subsequently osteoclastogenesis. Diphosphonates 74-89 TNF superfamily member 11 Homo sapiens 100-151 26337218-1 2015 Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Diphosphonates 261-276 TNF superfamily member 11 Homo sapiens 45-97 26337218-1 2015 Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Diphosphonates 261-276 TNF superfamily member 11 Homo sapiens 99-104 25173134-1 2014 Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-kappaB ligand (RANKL) antibody (Ab). Diphosphonates 169-184 TNF superfamily member 11 Homo sapiens 222-265 25820558-0 2015 RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Diphosphonates 60-74 TNF superfamily member 11 Homo sapiens 5-10 25820558-3 2015 The aim of the present study was to investigate the role of RANK/RANKL/OPG signaling pathway and, in parallel, to evaluate angiogenic and matrix mineralization processes in jaw bone necrotic samples obtained from bisphosphonate-treated subjects with established ONJ. Diphosphonates 213-227 TNF superfamily member 11 Homo sapiens 65-70 25173134-1 2014 Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-kappaB ligand (RANKL) antibody (Ab). Diphosphonates 169-184 TNF superfamily member 11 Homo sapiens 267-272 24982847-7 2014 With the new generation bisphosphonate zoledronic acid (ZA) or denosumab (anti-RANKL activity), one can reduce the number of patients who experience SREs, decrease the annual incidence of SREs and delay the median time to first SRE. Diphosphonates 24-38 TNF superfamily member 11 Homo sapiens 79-84 25274386-7 2014 Novel pharmaceutical therapy approaches with human monoclonal RANKL antibodies interfere in this osteodestructive process in an inhibitory manner and can represent alternative treatment options just as the osteosupportive therapy with bisphosphonates. Diphosphonates 235-250 TNF superfamily member 11 Homo sapiens 62-67 24443409-0 2014 Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. Diphosphonates 0-15 TNF superfamily member 11 Homo sapiens 106-111 19574937-3 2010 The effects of bisphosphonate treatment in OPG-RANKL system have not been fully elucidated. Diphosphonates 15-29 TNF superfamily member 11 Homo sapiens 47-52 24370033-1 2013 This study was aimed to investigate the effect of bortezomib combined with bisphosphonates on serum levels of DKK-1 and RANKL in multiple myeloma patients, and to evaluate its role in the therapy of osteolytic lesion. Diphosphonates 75-90 TNF superfamily member 11 Homo sapiens 120-125 24370033-7 2013 It is concluded that bortezomib combined with bisphosphonates obviously reduce the serum levels of DKK-1 and RANKL, thus has beneficial effect on osteolytic lesion. Diphosphonates 46-61 TNF superfamily member 11 Homo sapiens 109-114 20938793-8 2012 The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates. Diphosphonates 253-268 TNF superfamily member 11 Homo sapiens 206-211 20506157-0 2010 The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. Diphosphonates 146-160 TNF superfamily member 11 Homo sapiens 73-78 20506157-2 2010 In this work we analyzed RANKL expression in human bone marrow mesenchymal stromal cells and the effect of the bisphosphonate ibandronate on RANKL expression after IL-1beta activation of ERK pathway. Diphosphonates 111-125 TNF superfamily member 11 Homo sapiens 141-146 20506157-9 2010 Finally, the bisphosphonate ibandronate, that hindered activation of the MEK/ERK pathway significantly inhibited both basal and IL-1beta dependent RANKL expression by cells. Diphosphonates 13-27 TNF superfamily member 11 Homo sapiens 147-152 19836866-2 2010 Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases. Diphosphonates 174-189 TNF superfamily member 11 Homo sapiens 14-19 19836866-2 2010 Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases. Diphosphonates 174-189 TNF superfamily member 11 Homo sapiens 28-78 22901640-2 2013 A new alternative class of agents, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, are now available for use in these indications and have the potential to replace intravenous BPs. Diphosphonates 200-203 TNF superfamily member 11 Homo sapiens 35-86 22901640-2 2013 A new alternative class of agents, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, are now available for use in these indications and have the potential to replace intravenous BPs. Diphosphonates 200-203 TNF superfamily member 11 Homo sapiens 88-93 23212591-3 2013 The widely-used bisphosphonates or the new therapeutic option, denosumab an inhibitor of the receptor activator of NF-kappaB ligand (RANKL), interrupt this vicious cycle, inhibit tumor growth, and in clinical practice prevent skeleton-related events. Diphosphonates 16-31 TNF superfamily member 11 Homo sapiens 93-131 23212591-3 2013 The widely-used bisphosphonates or the new therapeutic option, denosumab an inhibitor of the receptor activator of NF-kappaB ligand (RANKL), interrupt this vicious cycle, inhibit tumor growth, and in clinical practice prevent skeleton-related events. Diphosphonates 16-31 TNF superfamily member 11 Homo sapiens 133-138 20938793-0 2012 Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Diphosphonates 13-28 TNF superfamily member 11 Homo sapiens 47-52 20938793-3 2012 The objective of this study was to evaluate the effect of bisphosphonates on the gene expression of receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in vitro. Diphosphonates 58-73 TNF superfamily member 11 Homo sapiens 100-138 20938793-3 2012 The objective of this study was to evaluate the effect of bisphosphonates on the gene expression of receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in vitro. Diphosphonates 58-73 TNF superfamily member 11 Homo sapiens 140-145 20938793-7 2012 The results showed a moderate enhancement of OPG gene expression whereas RANKL gene expression was strongly increased by nitrogen-containing bisphosphonates reaching a maximum after 14 days at high concentrations of 5 x 10(-5) M. Lower concentrations did not enhance the RANKL and OPG expression considerably. Diphosphonates 141-156 TNF superfamily member 11 Homo sapiens 73-78 20938793-8 2012 The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates. Diphosphonates 28-42 TNF superfamily member 11 Homo sapiens 81-86 20938793-8 2012 The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates. Diphosphonates 28-42 TNF superfamily member 11 Homo sapiens 206-211 19360288-13 2009 An increased expression of RANKL in stromal tissue surrounding bone metastases, RANK in osteoclasts and VEGF may serve as future targeted therapies possibly in conjunction with bisphosphonates. Diphosphonates 177-192 TNF superfamily member 11 Homo sapiens 27-32 16393773-0 2005 The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Diphosphonates 25-40 TNF superfamily member 11 Homo sapiens 67-72 18260178-10 2008 CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL. Diphosphonates 48-63 TNF superfamily member 11 Homo sapiens 174-179 16393773-2 2005 However, little is known about the effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Diphosphonates 45-60 TNF superfamily member 11 Homo sapiens 87-92 16393773-3 2005 Our study was intended to clarify effects of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Diphosphonates 45-60 TNF superfamily member 11 Homo sapiens 87-92 16393773-11 2005 Bisphosphonates inhibited glucocorticoid-induced RANKL expression, suggesting that these effects might be a new therapeutic mechanism for bisphosphonates. Diphosphonates 0-15 TNF superfamily member 11 Homo sapiens 49-54 16393773-11 2005 Bisphosphonates inhibited glucocorticoid-induced RANKL expression, suggesting that these effects might be a new therapeutic mechanism for bisphosphonates. Diphosphonates 138-153 TNF superfamily member 11 Homo sapiens 49-54 16101188-2 2005 We hypothesized that bisphosphonate treatment and the subsequent fall in serum calcium might induce changes in the RANK/RANKL/OPG system, which plays a pivotal role in the regulation of bone resorption. Diphosphonates 21-35 TNF superfamily member 11 Homo sapiens 120-125 15670755-0 2005 Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Diphosphonates 20-34 TNF superfamily member 11 Homo sapiens 87-92 14753746-0 2004 The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Diphosphonates 24-38 TNF superfamily member 11 Homo sapiens 68-73 14753746-5 2004 MATERIALS AND METHODS: We examined the effect of the most potent nitrogen-containing BP available, zoledronic acid (ZOL), on the expression of RANKL and osteoprotegerin (OPG), critical factors in the regulation of OC formation and activation, in primary osteoblast (OB)-like cells derived from human bone, using flow cytometry, ELISA, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), in situ immunofluorescence staining, and Western blotting. Diphosphonates 85-87 TNF superfamily member 11 Homo sapiens 143-148